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Lipid and polymer stabilized microbubbles are used in medicine as contrast agents for ultrasound imaging and are being
developed for the delivery of water soluble drugs to diseased areas of the body. However, many new therapeutics exhibit poor
water solubility or stability, which has led to the requirement for the development of effective hydrophobic drug delivery systems.
This study presents a new method to produce microbubbles coated with an oil layer capable of encapsulating hydrophobic drugs
and suitable for targeted, triggered drug release. This new method utilizes highly controllable ﬂow-focusing microﬂuidics with lipid
oil nanodroplets self-assembling and spreading at gas–aqueous interfaces. Oil layer inside microbubbles were produced with
diameters of 2.4 ± 0.3 μm (s.d., 1.6 μm) and at concentrations up to 106 bubbles per milliliter. The mechanism of oil layer inside
microbubble assembly and stability were characterized using methods including contact angle measurements, quartz crystal
microbalance with dissipation monitoring and ﬂuorescence resonance energy transfer imaging.
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INTRODUCTION
It has been estimated that up to 40% of all newly developed drugs
have poor water solubility.1,2 Many drugs also show poor stability
in water. Thus, while many of these drugs have shown good
results in vitro their efﬁcacy is reduced in vivo and in some cases
have been show to increase toxicity toward healthy tissue2. For
example, drugs such as Combretastatin A4, a vascular disrupting
agent proposed for the treatment of colorectal cancer, have
proven difﬁcult to deliver effectively due to their hydrophobicity3,
while drugs such as the anti-cancer agent Decitabine, a DNA
methyltransferase inhibitor, have been shown to undergo rapid
decomposition in water to inactive products4. A number of
hydrophobic drug encapsulation systems have been investigated
previously, such as porous nanoparticles1,5, sub-micron oil
emulsions6, and micelles7. The release mechanisms of these
systems can be either passive, for example, due to drug leakage
from the carrier, or active, due to environmental-triggered release,
for example, in response to local temperature or pH8,9. However,
such mechanisms often lead to unpredictable drug release proﬁles
when applied in vivo10. Therefore, a hydrophobic drug delivery
system with a controlled, externally activated, triggered release
mechanism could offer a considerable advantage over existing
technologies.
Lipid and polymer-shelled microbubbles (MBs) have been used
as contrast enhancing agents in ultrasound (US) imaging for over 30
years11. The compressibility of their gas core combined with its high
acoustic impedance mismatch against surrounding blood plasma
leads to a large scattering cross-section so that MBs provide a
higher echogenicity than tissue interfaces12–14. This makes MBs a
powerful tool in diagnostic US imaging of the cardiovascular system
and organs. MBs have more recently been shown to enhance
therapeutic delivery15, making them promising ‘theranostic’ agents,
with both ‘diagnostic’ and ‘therapeutic’ capabilities. US destruction
pulses can be used to trigger the release of encapsulated/attached
drug payload by destroying the MB vehicle at the target.
Alternatively, stable cavitation of MBs may be used to drive
sonoporation of the nearby cells and stream ﬂuid around the MBs,
thereby aiding drug uptake, and MB destruction can lead to
‘microjets,’ which are able to pierce endothelial lining allowing
improved efﬁcacy of drug injection15,16.
To date, these dual functional MBs have been formed in a
number of designs. MBs have been loaded with DNA/RNA in the
lipid shell17–19. They have been decorated with nanobeads18 and
vesicles14 for coating with and the encapsulation of hydrophilic
species, respectively. Examples of loading have included quantum
dots, luciferin, and propidium iodide20,21. With a simple lipid or
polymer shell structure, MBs have also been co-delivered with
hydrophilic species and drugs, for example, to overcome delivery
across the blood–brain barrier22 and enhance transdermal
transport of insulin and heparin23.
MBs are conventionally produced by sonication, mechanical
agitation, or microﬂuidics, typically through the use of a gas with
low water solubility and an aqueous solution of lipids or polymers.
MBs are required to be smaller than 8 μm to avoid the risk of
blood ﬂow complications such as arterial embolisms24,25. For the
production of more complex MB architectures, such as those with
drug payloads and molecular targeting, microﬂuidic approaches
offer greater control over MB size, reduced wastage of drug cargo
and targeting agents, and ease of cleaning the ﬁnal product14,26.
Microﬂuidic-based MB preparation typically utilizes ﬂow-focusing
(FF) geometries, where a gas phase is pinched off at a nozzle to
form a MB, by a continuous aqueous phase containing a surfactant
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agent, usually lipids. Hettiarchi and Talu have previously shown
high levels of size control, producing lipid-coated, perﬂuorocarbon
core 1–5 μm MBs with polydispersity indices as low as 2–5%27–29.
We have also developed an on-chip ‘microspray regime’ for MB
formation, which can produce high concentrations of MBs (4109
MB mL− 1) with an average size of 1.5 μm14,30.
One possible route for the incorporation of drugs onto the MB
architecture is to thicken the MB shell with an oil layer, giving an
oil layer inside MB (OLI-MB). These MBs would allow hydrophobic
drugs to be held within the oil component, while retaining their
US properties for imaging and active release. Unger et al.31 were
the ﬁrst to incorporate an oil layer into MBs, which they termed
acoustically active lipospheres (AALs). Since then AALs have been
reproduced and further characterized by other groups. AALs have
been produced through the mechanical agitation of lipid solution,
oil (primarily soybean or triacetin), and a gas such a perﬂuor-
obutane (C4F10), resulting in MBs of 2.9 μm average diameter with
a thick oil shell capable of high drug loading per MB31, but large
MB–MB variability with sizes ranging from 1 to 10 μm and drug
loading being inconsistent between vehicles32,33. Oil layers can
range from 500 to 1000 nm and 300 to 700 nm for triacetin and
soybean oil, respectively, with some vehicles containing no gas at
all33,34. It is thought that this large MB to MB variability is due to
the production method’s chaotic nature, and lack of control over
gas encapsulation. In terms of their US capabilities, AALs’ thick oil
layer is thought to lead to viscous dampening34. Compared to
non-oil-MBs, AALs fragmentation by US is signiﬁcantly more
difﬁcult, with a high mechanical index of 0.67–2.0, and a ﬁvefold
higher pulse length being required for MB destruction32,34. During
tests of AALs on cells, 30% of the cells were found to die from the
US alone35. In 2009, Lentacker et al.35 concluded that it remained
difﬁcult to efﬁciently release drugs from AALs using medically
relevant US. Colombo and Edirisinghe demonstrated the produc-
tion of ~ 50 μm multi-layered OLI-MBs through the use of coaxially
arranged needles, providing more monodisperse MBs36,37. How-
ever, this method is in part limited by the needles’ inner and outer
diameters, often leading to MBs that are larger than that required
for medical applications. Lee and Zhang have previously demon-
strated methods for OLI-MB and multi-layered MB production
using a three-phase FF system and a system of two subsequent
two-phase FF nozzles, respectively10,25,38. However, control of
three different phases on-chip is inherently difﬁcult and often
leads to poor MB yields. As depicted in Figure 1, we propose a
new, simple method for the production of MBs with an
internalized thin oil layer between the gas core and lipid shell,
OLI-MBs. Here we produce OLI-MBs using a FF system but include
an emulsion of oil nanodroplets stabilized by a lipid monolayer
shell, termed lipid oil nanodroplets (LONDs), into the aqueous
phase. The LONDs undergo adsorption, rupture, and spreading at
the gas–water interface, leading to the formation of a tens of
nanometers thick oil layer around the MB. By including the LONDs
in the aqueous phase, the microﬂuidics is brought back to a two-
phase system, permitting easier control over MB production and
potentially allowing a broader range of hydrophobic solvents to
be used for delivery. A combination of contact angle measure-
ments and quartz crystal microbalance with dissipation (QCM-D)
monitoring was used to identify the mechanisms of OLI-MB
formation while ﬂuorescence microscopy, including ﬂuorescence
resonance energy transfer (FRET), was used to conﬁrm the ﬁnal
OLI-MB structure.
MATERIALS AND METHODS
Materials
The lipid used in this work was 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC), purchased from Avanti Polar Lipids
(Alabaster, Al, USA). Squalane oil (Sigma-Aldrich, Dorset, UK) was
used as the hydrophobic carrier phase. Phosphate-buffered saline
(PBS) was prepared by dissolving one 5 g tablet of PBS powder
(Life Technologies, Carlsbad, CA, USA) in 500 mL of MilliQ water
and ﬁltered through a 200 nm cellulose membrane syringe ﬁlter
(Sartorius Stedim, Epsom, UK) prior to use.
Contact angles measurement and surface energy
Contact angle measurements of oil droplets at the water/lipid–air
interface were performed. These were used to calculate the
interfacial free energies of an OLI-MB, and to estimate the total
interfacial energy of a speciﬁc OLI-MB structure compared to other
conformations of oil and air in water in the presence of lipids.
A circular Teﬂon dish (6 cm diameter) was ﬁlled with MilliQ to
allow a meniscus to form above the top of the dish walls. This
meniscus was aspirated off before the dish was reﬁlled. This was
repeated a minimum of ﬁve times to remove any surface
contaminants. This set up was analogous to a Langmuir Blodgett
(LB) trough. POPC lipid, solubilized in chloroform at 1 mg mL− 1,
was added gradually to the water surface. This gave surface
concentrations of either no lipid or enough lipid that the surface
pressure was increased to just before the lipid layer collapsed at
the dish edge, which was assumed to be at the collapse pressure.
The sessile drop technique was used for contact angle measure-
ment, using a First Ten Angstroms instrument, by depositing a
droplet of oil at the air–water/lipid interface using a square cut
needle. Images of the oil droplet were analyzed in ImageJ to
measure both the left and right contact angles. At least ﬁve
droplets were measured for each lipid monolayer condition. These
contact angles were used to calculate the water/lipid–oil surface
tension and total surface energies, described below.
LOND production
LONDs were formed via two methods, either by tip sonication or a
two-stage ultra-ﬁne homogenization process (in a similar method
to that presented by Mico et al.39). 3,3′-Dioctadecyloxacarbocya-
nine perchlorate (DiO), and dioctadecyl-3,3,3′,3′-tetramethylindo-
carbocyanine perchlorate (DiI) (Sigma-Aldrich, Dorset, UK) were
encapsulated into the oil as drug mimics, and for optical
quantitative purposes, by sonication for 30 min at room tempera-
ture, at a concentration of 1 mg mL− 1.
LOND formation via tip sonication. An aliquot of 10 mg POPC
lipid was dissolved in 1:1 chloroform–methanol, dried under
nitrogen in a glass vial for 30 min, and then re-dispersed in 930 μL
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of PBS (Thermo Fisher Scientiﬁc, Waltham, MA, USA). An aliquot of
70 μL of oil was added. To form a LOND emulsion, the solution
was vortexed for 30 s, then tip sonicated at 200 W, 20% power,
100% duty cycle, for 15 min in a 4 °C cooled jacketed glass vessel.
The LOND solution was dialysed utilizing a 100 kDa pore-size
membrane for over 12 h to remove non-encapsulated ﬂuoro-
phore, and to reduce any excess lipid in solution until in
equilibrium with the LONDs.
LOND formation via homogenization. An aliquot of 100 mg of
dried lipid was re-dispersed in 3.3 mL of PBS and 700 μL of oil was
added. To form an oil droplet emulsion, the solution was vortexed,
coarsely homogenized with a Polytron PT1300 D (Kinematica AG,
Luzern, Switzerland) at 12.5 krpm, 40 °C, and atmospheric pressure
for 10 min. The emulsion was made up to 10 mL with PBS buffer
and, to form a LOND emulsion, ﬁnely homogenized under high
pressure in an Avestin EmulsiFlex-C5 (Avestin Europe GmbH,
Mannheim, Germany) at ~ 175 MPa, 4 °C for 20 min. The emulsion
was then ﬁltered using a KrosFlow Research IIi Tangential Flow
Filtration System (SpectrumLabs Europe, Breda, the Netherlands)
at 100 kDa, 45 mL min − 1 for at least 2 h for the same reason as
dialysis above.
LOND sizing and concentration measurements were performed
using a Zetasizer and NanoSight (Malvern Instruments, Malvern,
UK). LONDs were typically produced at ~ 170 nm diameter and
1013 LONDs per milliliter.
QCM-D: LOND spreading mechanics
QCM-D was used to study LOND interactions with hydrophobic
solid surfaces in an aqueous environment as a mimic to the air–
water MB interface.
Octadecanethiol (Sigma-Aldrich, Dorset, UK) was used for
coating gold-coated QCM-D crystals (Q-Sense AB, Stockholm,
Sweden). Prior to the experiments, the crystals were thoroughly
cleaned by UV-ozone cleaning for 20 min, followed by immersion
in Decon 90 and then MilliQ while in a sonication bath, and ﬁnally
vigorous agitation in isopropanol. The crystals were kept in each
solution for about 10 min. This process was followed by an N2 dry
and again by UV-ozone for 20 min. Hydrophobic self-assembled
monolayers were formed on the gold-coated crystals by immer-
sion of the crystals in octadecanethiol in ethanol (1 mg mL− 1) for
12 h, after which they were rinsed with ethanol, to remove excess
octadecanethiol, and MilliQ. For all QCM-D experiments, water
contact angle measurements were performed on a control QCM-D
crystal to conﬁrm hydrophobicity, using a First Ten Angstroms
instrument with MilliQ droplets.
A Q-Sense E4 (Q-Sense AB, Stockholm, Sweden) was used to
monitor the interaction between the LONDs and the QCM-D
crystal. Crystals were allowed to equilibrate for at least 1 h in
degassed PBS, ﬂowing at 14 μL min− 1. The 5th, 7th, 9th, and 11th
overtones were recorded and used in the analysis. The LONDs
were introduced in to the ﬂow chambers at a dilution of 1012
LONDs per mL in PBS, at 140 μL min− 1. The ﬂow was then stopped
for ~ 2 h until no further frequency or dissipation changes were
observed. PBS was used to rinse the system, in order to remove
any unattached material (140 μL min− 1). The Sauerbrey and the
Voigt-viscoelastic models were ﬁtted to the above harmonics to
calculate the mass adhered to the crystal during the experiment
and estimate the thickness of the oil–lipid layer formed.
Microﬂuidic OLI-MB production
Microﬂuidic FF devices were designed in Leeds and fabricated by
Epigem Ltd (Redcar, UK) in PMMA and SU-8, as described
previously and shown schematically in Figure 1a9. LOND solution
was diluted to 1012 LONDs per mL in 10% v/v glycerol, 4 mg mL− 1
NaCl. LOND solution ﬂow rates of 15–50 μL min− 1 were delivered
via a syringe pump (Aladdin, World Precision Instruments,
Sarasota, FL, USA), passing ﬁrst through a 200 nm ﬁlter (Sartorius
Stedim, UK) to remove any oil that was not successfully
homogenized or from LONDs that had destabilized over time.
Flow of the LOND solution in the absence of MB production did
not result in the formation of larger agglomerates but rather
yielded oil emulsion comparable to the initial LOND solution,
indicating their relative stability due to the lipid shell. Indeed, we
have found these solutions to be stable for over 6 weeks39. C4F10
gas (F2 Chemicals, Preston, UK) pressures of 20–34.5 kPa were
regulated by a digital gas ﬂow controller (Alicat Scientiﬁc, Tucson,
AZ, USA). At the nozzle, the gas was pinched off and stabilized as a
MB by the LOND solution. The MB solution contained 10 μL of
liquid perﬂuorohexane (C6F14) per 1 mL of precursor MB solution
to extend MB lifetime by intercalation of the C6F14 into the MB
shell40. High frame rate imaging (FASTCAM SA-X, Photron, San
Diego, CA, USA) between 10 and 50 kfps, performed on an
inverted light microscope (Eclipse Ti-U, Nikon, Tokyo, Japan),
was used to observe single MB pinch-off and ﬂow immediately
after the nozzle during production. For size and concentration
measurements, 50 μL of the MB solution, taken from the middle of
the solution immediately after gentle agitation to prevent pre-
concentration due to bubble buoyancy, was placed in a 120 μm
deep, BSA Dorset, Sigma-Aldrich, UK) coated, glass chamber and
observed under dark ﬁeld (Eclipse Ti-U, Nikon, Tokyo, Japan) with
an oil immersion × 100 objective.
For the determination of MB lifetime, three 50 μm deep, BSA-
coated, wax sealed, glass observation chambers were prepared
and the MBs were observed using dark-ﬁeld microscopy, as a
function of time. The MB diameter and concentration were
measured using ImageJ.
OLI-MB washing
Microﬂuidic cell-traps were used to trap and wash larger OLI-MBs
to conﬁrm the structure of the MBs41. The traps were made from
PDMS, and were designed to catch 45 μm MBs, to allow higher
resolution imaging of OLI-MB structures. Prior to any use, the
microﬂuidic devices were washed with 70% ethanol to remove
any air, followed by 1 mL MilliQ and 1 mL of 1 mg mL− 1 BSA in
PBS at 100 μL min− 1 to reduce non-speciﬁc binding of excess
LONDs to the cell-trap walls. The MB sample was then introduced
to the device at 5 μL min− 1 over 20–30 min (allowing enough MBs
to be trapped), before being washed by PBS at 10 μL min− 1 for
30 min. All observations were made using a Confocal Laser
Scanning Platform Leica TCS SP8 on a DMi8 microscope (Leica
Microsystems, Milton Keynes, UK) with a 488 nm excitation laser
and a 561–582 nm emission window. LAS X software was used for
image capture and processing.
FRET LOND interactions on MBs
FRET was used to infer LOND destablization and LOND to LOND
mixing at the MB gas–aqueous interface. Separate preparations of
LONDs were made containing either a FRET donor (DiO) or a FRET
acceptor (DiI) dye42,43. These solutions were mixed 1:1 and then
diluted to 1012 LONDs per ml in PBS. This mixed LOND solution
was then used to produce MBs microﬂuidically, as above. MB
samples were loaded into 50 μm deep, BSA-coated glass-viewing
chambers. Fluorescence was then observed on the above confocal
system with a × 40 objective, using a 488 nm excitation laser, and
500–520 nm and 561–582 nm emission windows for the donor
and acceptor, respectively. In order to identify the enhanced
FRET ﬂuorescence, FRET donor LOND + FRET acceptor LOND
samples were compared to control donor + non-ﬂuorescent/
empty and empty + acceptor samples. As in Equation (1), the
intensity at the MB surface in both control images was removed
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from the donor + acceptor image to reveal the FRET signal44,45.
FRETf¼ FRETi - ImaxDonorþEmpty þ ImaxEmptyþAcceptor
  ð1Þ
where FRETf is the ﬁnal FRET image, FRETi is the initial FRET (donor
+acceptor) image, and I is the intensity.
RESULTS AND DISCUSSION
Contact angle measurement and surface energy calculation
Figure 2 shows a schematic of a droplet of oil at the air–water
(modiﬁed with lipid) interface, and images of droplets at the air–
water interface in the absence and presence of an adsorbed POPC
lipid layer. The squalane contact angle decreased from 25° to 6° in
the presence of POPC. The surface tension values of squalane
reported in the literature vary between 25 and 30 mNm− 1
(Refs. 46–50). While that of the lipid modiﬁed air–water interface is
26–27 mNm− 1 for POPC at the collapse pressure51–54. The oil–
water interfacial tension was calculated using the balance of the
interfacial tensions for oil in contact with a water sub-phase and
air spectator phase (see Equation (s1) from supplementary
information). This was found to be 55 mNm− 1 without lipid and
⩽ 1.9 mN m− 1 with POPC.
During OLI-MB formation, we form the MBs through ﬂow focus
‘pinch-off’ of the gas in the presence of an aqueous solution
containing LONDs with an average diameter of ~ 170 nm, as
shown schematically in Figure 2c(i). If we assume a process in
which LONDs adsorb then rupture to form a uniform oil layer at
the water/gas interface (vide infra), then we expect of the order of
350 LONDs per MB. With this assumption, we can estimate the
total surface energies for the initial starting state (Figure 2c(i)) and
the different possible end conﬁgurations; (Figures 2c(ii) and (iii)). In
going from the initial conﬁguration (Figure 2c(i)) to the desired
lipid-coated oil-shell surrounding a MB (Figure 2c(ii)) there would
be a 2.6-fold reduction in the total surface free energy. In contrast,
the scenario in which the LONDs agglomerate into a larger oil
droplet, and the MB remains uncoated (Figure 2c(iii)), would lead
to a similar total surface free energy to the initial conﬁguration.
The conclusion drawn here is that, since the OLI-MB structure was
calculated to have the lower total surface free energy, it is
energetically preferential as a ﬁnal structure, and so formation of
the structure is plausible.
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Figure 2 (a) A schematic of the oil/lipid/water interface, and images
of (b) (i) a squalane oil droplet at an air/MilliQ interface and (ii) in the
presence of POPC lipid, for the contact angle and total surface
energy values calculated. A minimum of ﬁve droplets were imaged
and their contact angles averaged, calculating standard error, for
each monolayer type. (c) Schematic of the possible oil, gas and lipid
conﬁgurations, showing (i) the initial state of LONDs around a MB
without a surfactant/lipid shell, leading to (ii) an OLI-MB or (iii) the
LONDs coalescing and the MB remaining unchanged. LOND, lipid oil
nanodroplets; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line; OLI-MB, oil layer inside MB.
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QCM-D: LOND spreading mechanics
To mimic the LOND/MB interaction, we performed QCM-D of
LOND interactions with model hydrophobic surfaces. Figure 3
shows the changes in frequency (ΔF) and dissipation (ΔD) on
interaction of LONDs with a hydrophobic QCM-D crystal. Initially,
there was a rapid, negative increase in ΔF accompanied by a rapid,
positive increase in ΔD, indicative of the absorption of LONDs and
the formation of a heterogeneous, non-uniform surface layer,
which couples strongly to the aqueous phase. Over the following
~ 10 min ΔF decreased and reached a plateau. Simultaneously, the
ΔD decreased to a stable value of ~ 15 × 10− 6. This behavior is
similar to that of bilayer formation via vesicle adsorption and
rupture on hydrophilic surfaces55–57. We propose a similar two-
stage mechanism to explain our observations, (i) the attachment
of LONDs (possibly partial wetting of the surface) followed by (ii)
the slower spreading of droplets on the surface, leading to the
detachment of entrapped water and possibly some oil. At the
onset of washing the chambers, fresh LONDs were introduced to
the surface, leading to a smaller increase in ΔF and ΔD, followed
by the PBS wash, which resulted in the signal recovering to the
‘before wash’ level and further remaining stable. Changes in
frequency provided an estimated value for the thickness of the oil
layer formed during LOND rupture to be between 10 and 20 nm.
This result gave an estimate of the order of 70 LONDs per MB.
Recalculating the previous total surface free energies in respect to
this still showed a 2.5-fold reduction when forming an OLI-MB
from LONDs.
Microﬂuidic OLI-MB production
Figure 4a shows microﬂuidic OLI-MB production. Optimized
production required low gas pressure (20–34.5 kPa), and aqueous
ﬂow rates between 20 and 25 μL min− 1, to prevent coalescence of
the pinched off gas. This could be due to the slower adsorption
and rupturing of LONDs at the gas–aqueous interface to stabilize
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the MBs, as depicted in Figure 1a. Production rates were ~ 5× 103
OLI-MBs per s.
Figures 4b and c show off-chip imaging of the OLI-MBs and an
associated size distribution. While OLI-MBs were routinely
produced on-chip at 9.0 ± 1.8 μm diameter (s.d., 1.4 μm), off-chip
imaging showed a repeatable reduction in MB size to ~ 0.3 times
their initial size, giving OLI-MBs of 2.4 ± 0.3 μm (s.d., 1.6 μm) and a
concentration of 6.2 ± 0.8 × 106 MBs mL− 1. This size change was
due to gas leakage from the interior of the MB after production. A
MB’s diameter effectively stabilizes when the lipid shell concen-
trates from an equilibrium state to being close packed at the
collapse pressure. This effect has been shown previously on DPPC:
DPPA:DPPE-PEG5000 MBs formed using FF devices, where MBs
shrank to 0.39 times initial size58.
Figure 5 shows the change in OLI-MB concentration and
diameter over time. There was a sharp initial decrease in
concentration over the ﬁrst 90 min, after which the bubble
concentration appeared stable for the duration of the measure-
ment. During this period, the MB population showed a modest
increase in size, presumably due to Ostwald ripening29.
Figure 6 shows a trapped OLI-MB after the washing step to
remove excess LONDs from the surrounding solution. The
persistent ﬂuorescent halo suggested that the oil component of
the OLI-MBs was stable against shear forces and the removal of
excess oil and lipid from the surrounding solution. All MBs
observed in these traps after washing steps were recorded with
some degree of ﬂuorescent shell, indicating that the OLI-MB
samples had been formed without any non-oil-MBs.
FRET LONDs: observing OLI-MB oil layer
Figure 7a shows a schematic for a FRET experiment to
demonstrate the coalescence of LONDs and the mixing of their
contents. Figure 7b shows the ﬂuorescence signatures expected
for three potential outcomes of LONDs at a MB’s gas/water
interface. Figure 7c shows the experimental acceptor emission
following the interaction of LONDs containing donors and
acceptors. FRET was shown to occur at the MB surface. As
detailed by Figures 7a and b, observation of FRET signal provides
evidence that the LONDs did adsorb and rupture at the MB
interface, where oil and loaded ﬂuorophores from both LOND
populations mixed together. When compared to the QCM-D
results for LONDs at a water–hydrophobic solid (as opposed to
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Figure 7 (a and b) Schematic of FRET-loaded LONDs for OLI-MB formation. Showing what would be observed if (b(i)) the LONDs contributed
lipid for MB stabilization but no oil/ﬂuorophore, donor (D) excitation leading to (a(i) and b(ii)) D emission if the nanodroplets remained stable
at the MB surface, and (a(ii) and b(iii)) acceptor (A) emission if the nanodroplets merged/spread. (c) FRET OLI-MBs, formed from a combination
of D, A, and non-ﬂuorescent/empty (E) LONDs. All observation are of the A emission window, 561–582 nm. FRET signal image (c(iv)) calculated
using Equation (1). FRET, ﬂuorescence resonance energy transfer; LOND, lipid oil nanodroplets; OLI-MB, oil layer inside MB.
a b
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Figure 6 A microﬂuidic OLI-MB in a microﬂuidic cell-trap after washing
with PBS. (a) Bright-ﬁeld image and (b) ﬂuorescence image of a MB
incorporating DiI in the squalane shell. OLI-MB, oil layer inside MB.
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gas) interface, these results appear to show a similar mechanism
for the formation of a continuous oil layer around the gas core,
resulting in OLI-MBs.
Additional work
Tripropionin OLI-MBs. Squalane is a non-polar oil with a very low
water solubility59. Tripropionin is a partially water soluble
triglyceride (3.07 mg mL− 1 at 37 °C) used as ﬂavoring agent60.
By expanding the above work to form OLI-MBs from tripropionin
LONDs, solubilization of a larger range of non-polar to partially
polar drugs in to the oil phase would be possible. As such, the
microﬂuidic OLI-MB production and wash steps have been
repeated using tripropionin (Sigma-Aldrich, UK) LONDs. (See
Supplementary Figure S1) Tripropionin OLI-MBs have been
produced at 2.1 ± 0.1 μm diameter (s.d., 0.8 μm), though with a
lower concentration of 104 OLI-MBs per milliliter.
CONCLUSION
We have presented a new approach to preparing MBs with an
internalized oil component utilizing simple ﬂow focussed micro-
ﬂuidics coupled with self-assembly. Squalane OLI-MBs were
produced on-chip with diameters of 9.0 ± 1.8 μm that subse-
quently shrank and stabilized to a diameter of ~ 2.4 ± 0.3 μm (s.d.,
1.6 μm), without any OLI-MBs shown above 8 μm. The ﬁnal OLI-MB
size has made this formation route of practical use for producing
these MBs for clinical application. Off-chip OLI-MBs had a
concentration of 6.2 ± 0.8 × 106 OLI-MBs per mL. The mechanism
of formation was via the adsorption and spreading of LONDs at
the hydrophobic–hydrophilic interface during and shortly after MB
‘pinch-off’. This process was mimicked using QCM-D, where the
formation of a uniform oil layer was conﬁrmed from changes in
the frequency and dissipation. The continuous nature of the oil
shell was conﬁrmed using FRET imaging of MBs formed from two
LOND species (one containing a donor species and the other an
acceptor species). We have also shown that this is a general
approach that can be used with different oil types. These
architectures hold potential for the encapsulation and delivery
of poorly water soluble and water-stable drugs. For potential
clinical application of OLI-MBs, it may be advantageous to
selectively separate the OLI-MBs from the excess LONDs they
are formed in. This is possible based on the buoyancy of the
different particles61.
ACKNOWLEDGEMENTS
The authors thank the Leeds Microbubble Consortium for their continued support
and discussions. Stuart Weston at University of Leeds, Physics workshop, for the
construction of the manifolds for the microﬂuidic platform. We gratefully acknowl-
edge the ﬁnancial sponsorship of the EPSRC (Grant No. EP/K023845/1) and the EPSRC
Centre for Doctoral Training in Molecular-Scale Engineering (Grant No. 1229421). SDE
like to thank the NIHR-HTC for Colorectal Therapies, the MRC-CiC, and the Wellcome
Trust ISSF Scheme for ﬁnancial support. The data presented in this article are openly
available from the University of Leeds Data Repository http://doi.org/10.5518/153.
COMPETING INTERESTS
The authors declare no conﬂict of interest.
REFERENCES
1 Straub JA, Chickering DE, Lovely JC et al. Intravenous hydrophobic drug delivery:
A porous particle formulation of paclitaxel (AI-850). Pharmaceutical Research 2005;
22: 347–355.
2 Kumar A, Sahoo SK, Padhee K et al. Reveiw on solubility enhancement techniques
for hydrophobic drugs. International Journal of Pharmaceutical Compounding
2011; 2: 1–7.
3 Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nature
Reviews Cancer 2005; 5: 423–435.
4 Rogstad DK, Herring JL, Theruvathu JA et al. Chemical decomposition of 5-aza-2’-
deoxycytidine (Decitabine): Kinetic analyses and identiﬁcation of products by
NMR, HPLC, and mass spectrometry. Chemical Research in Toxicology 2009; 22:
1194–1204.
5 Song B, Wu C, Chang J. Controllable delivery of hydrophilic and hydrophobic
drugs from electrospun poly(lactic-co-glycolic acid)/mesoporous silica nano-
particles composite mats. Journal of Biomedical Materials Research - Part B Applied
Biomaterials 2012; 100B: 2178–2186.
6 Gupta S, Moulik SP, Lala S et al. Designing and testing of an effective oil-in-water
microemulsion drug delivery system for in vivo application. Drug Delivery 2005;
12: 267–273.
7 Aliabadi HM, Elhasi S, Mahmud A et al. Encapsulation of hydrophobic drugs in
polymeric micelles through co-solvent evaporation: The effect of solvent com-
position on micellar properties and drug loading. International Journal of Phar-
maceutics 2007; 329: 158–165.
8 Ganta S, Devalapally H, Shahiwala A et al. A review of stimuli-responsive nano-
carriers for drug and gene delivery. Journal of Controlled Release 2008; 126:
187–204.
9 Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug
delivery—a review of the state of the art. European Journal of Pharmaceutics and
Biopharmaceutics 2000; 50: 161–177.
10 Hettiarachchi K, Lee AP, Zhang S et al. Controllable microﬂuidic synthesis of
multiphase drug-carrying lipospheres for site-targeted therapy. Biotechnology
Progress 2009; 25: 938–945.
11 Stride E, Saffari N. Microbubble ultrasound contrast agents: A review. Proceedings
of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine
2003; 217: 429–447.
12 Chatterjee D, Sarkar K. A Newtonian rheological model for the interface of
microbubble contrast agents. Ultrasound in Medicine & Biology 2003; 29:
1749–1757.
13 Dalla Palma L, Bertolotte M. Introduction to ultrasound contrast agents: Physics
overview. European Radiology 1999; 9: S338–S342.
14 Peyman SA, Abou-Saleh RH, McLaughlan JR et al. Expanding 3D geometry for
enhanced on-chip microbubble production and single step formation of lipo-
some modiﬁed microbubbles. Lab on a Chip 2012; 12: 4544.
15 Pitt WG, Husseini GA, Staples BJ. Ultrasonic drug delivery – a general review.
Expert Opinion on Drug Delivery 2004; 1: 37–56.
16 van Wamel A, Kooiman K, Harteveld M et al. Vibrating microbubbles poking
individual cells: drug transfer into cells via sonoporation. Journal of Controlled
Release 2006; 112: 149–155.
17 Panje CM, Wang DS, Pysz MA et al. Ultrasound-mediated gene delivery with
cationic versus neutral microbubbles: Effect of DNA and microbubble dose on in
vivo transfection efﬁciency. Theranostics 2012; 2: 1078–1091.
18 Liu Y, Miyoshi H, Nakamura M. Encapsulated ultrasound microbubbles: Ther-
apeutic application in drug/gene delivery. Journal of Controlled Release 2006; 114:
89–99.
19 Bekeredjian R, Chen S, Frenkel PA et al. Ultrasound-targeted microbubble
destruction can repeatedly direct highly speciﬁc plasmid expression to the heart.
Circulation 2003; 108: 1022–1026.
20 Peyman SA, Abou-Saleh RH, Evans SD. Microbubbles for therapeutic delivery.
Therapeutic Delivery 2013; 4: 539–542.
21 McLaughlan J, Ingramy N, Abou-Saleh R et al. High-frequency subharmonic
imaging of liposome-loaded microbubbles. IEEE International Ultrasonics Sym-
posium, IUS; 21–25 July 2013; Prague, Czech Republic; 2013: 1501–1504;
doi: 10.1109/ULTSYM.2013.0381.
22 Choi JJ, Pernot M, Brown TR et al. Spatio-temporal analysis of molecular delivery
through the blood–brain barrier using focused ultrasound. Physics in Medicine &
Biology 2007; 52: 5509–5530.
23 Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of
transdermal drug delivery. Nature Reviews Drug Discovery 2004; 3: 115–124.
24 Tinkov S, Coester C, Serba S et al. New doxorubicin-loaded phospholipid micro-
bubbles for targeted tumor therapy: In-vivo characterization. Journal of Controlled
Release 2010; 148: 368–372.
25 Shih R, Bardin D, Martz TD et al. Flow-focusing regimes for accelerated production
of monodisperse drug-loadable microbubbles toward clinical-scale applications.
Lab on a Chip 2013; 13: 4816.
26 Seo M, Gorelikov I, Williams R et al. Microﬂuidic assembly of monodisperse,
nanoparticle-incorporated perﬂuorocarbon microbubbles for medical imaging
and therapy. Langmuir 2010; 26: 13855–13860.
27 Hettiarachchi K, Talu E, Longo ML et al. On-chip generation of microbubbles as a
practical technology for manufacturing contrast agents for ultrasonic imaging.
Lab on a Chip 2007; 7: 463–468.
28 Talu E, Hettiarachchi K, Zhao S et al. Tailoring the size distribution of ultrasound
contrast agents: Possible method for improving sensitivity in molecular imaging.
Molecular Imaging 2007; 6: 384–392.
Oil layer inside microbubbles
AH Churchman et al
7
Microsystems & Nanoengineeringdoi:10.1038/micronano.2017.87
29 Talu E, Hettiarachchi K, Powell RL et al. Maintaining monodispersity in a micro-
bubble population formed by ﬂow-focusing. Langmuir 2008; 24: 1745–1749.
30 Peyman SA, McLaughlan JR, Abou-Saleh RH et al. On-chip preparation of
nanoscale contrast agents towards high-resolution ultrasound imaging. Lab on a
Chip 2016; 16: 679–687.
31 Unger EC, McCreery TP, Sweitzer RH et al. Acoustically active lipospheres con-
taining paclitaxel: a new therapeutic ultrasound contrast agent. Investigative
Radiology 1998; 33: 886–892.
32 Kooiman K, Böhmer MR, Emmer M et al. Oil-ﬁlled polymer microcapsules for
ultrasound-mediated delivery of lipophilic drugs. Journal of Controlled Release
2009; 133: 109–118.
33 Hettiarachchi K, Lee AP, Feingold SG et al. Ultrasonic analysis of precision-
engineered acoustically active lipospheres produced by microﬂuidic. Proceedings
- IEEE Ultrasonics Symposium; 20-23 Sept. 2009; Rome, Italy; 2009: 1302–1305;
doi: 10.1109/ULTSYM.2009.5441565.
34 May DJ, Allen JS, Ferrara KW. Dynamics and fragmentation of thick-shelled
microbubbles. IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control
2002; 49: 1400–1410.
35 Lentacker I, De Smedt SC, Sanders NN. Drug loaded microbubble design for
ultrasound triggered delivery. Soft Matter 2009; 5: 2161.
36 Ahmad Z, Zhang H, Farook U et al. Generation of multilayered structures for
biomedical applications using a novel tri-needle coaxial device and
electrohydrodynamic ﬂow. Journal of the Royal Society Interface 2008; 5:
1255–1261.
37 Stride E, Edirisinghe M. Novel microbubble preparation technologies. Soft Matter
2008; 4: 2350.
38 Zhang H, Meng H, Sun Q et al. Multi-layer microbubbles by microﬂuidics. Scientiﬁc
Research 2013; 5: 146–148.
39 Mico V, Charalambous A, Peyman SA et al. Evaluation of lipid-stabilised tripro-
pionin nanodroplets as a delivery route for combretastatin A4. International
Journal of Pharmaceutics 2017; 526: 547–555.
40 Abou-Saleh RH, Peyman SA, Johnson BRG et al. The inﬂuence of intercalating
perﬂuorohexane into lipid shells on nano and microbubble stability. Soft Matter
2016; 12: 7223–7230.
41 Di Carlo D, Aghdam N, Lee LP. Single-cell enzyme concentrations, kinetics, and
inhibition analysis using high-density hydrodynamic cell isolation arrays. Analy-
tical Chemistry 2006; 78: 4925–4930.
42 Aguilar-Castillo BA, Santos JL, Luo H et al. Nanoparticle stability in biologically
relevant media: inﬂuence of polymer architecture. Soft Matter 2015; 11:
7296–7307.
43 Chen H, Kim S, Li L et al. Release of hydrophobic molecules from polymer micelles
into cell membranes revealed by Forster resonance energy transfer imaging.
Proceedings of the National Academy of Sciences of the USA 2008; 105: 6596–6601.
44 Xia Z, Liu Y. Reliable and global measurement of ﬂuorescence resonance energy
transfer using ﬂuorescence microscopes. Biophysical Journal 2001; 81: 2395–2402.
45 Zou P, Chen H, Paholak HJ et al. Noninvasive ﬂuorescence resonance energy
transfer imaging of in vivo premature drug release from polymeric nanoparticles.
Molecular Pharmaceutics 2013; 10: 4185–4194.
46 Kohler SPK, Reed SK, Westacott RE et al. Molecular dynamics study to identify the
reactive sites of a liquid squalane surface. Journal of Physical Chemistry B 2006;
110: 11717–11724.
47 Saecker ME, Govoni ST, Kowalski DV et al. Molecular beam scattering from liquid
surfaces. Science 1991; 252: 1421–1424.
48 Fowkes FM, Riddle FL, Pastore WE et al. Interfacial interactions between self-
associated polar liquids and squalane used to test equations for solid-liquid
interfacial interactions. Colloids and Surfaces 1990; 43: 367–387.
49 Bascom WD, Cottington RL, Singleterry CR. Dynamic surface phenomena in the
spontaneous spreading of oils on solids. Advances in Chemistry 1964; 43: 355–379.
50 Phillips LF. A geometrical explanation for the enhanced small-scale roughness of
a liquid surface. The Journal of Physical Chemistry B 2004; 108: 1986–1991.
51 Pownall HJ, Pao Q, Brockman HL et al. Inhibition of lecithin-cholesterol acyl-
transferase by diphytanoyl phosphatidylcholine. Journal of Biological Chemistry
1987; 262: 9033–9036.
52 Smith EC, Crane JM, Laderas TG et al. Metastability of a supercompressed ﬂuid
monolayer. Biophyscial Journal 2003; 85: 3048–3057.
53 Domenech O, Torrent-Burgues J, Merino S et al. Surface thermodynamics study of
monolayers formed with heteroacid phospholipids of biological interest. Colloids
Surfaces B Biointerfaces 2005; 41: 233–238.
54 Domènech Ò, Sanz F, Montero MT et al. Thermodynamic and structural
study of the main phospholipid components comprising the mitochondrial inner
membrane. Biochimica et Biophysica Acta(BBA)-Biomembranes 2006; 1758: 213–221.
55 Richter RP, Brisson AR. Following the formation of supported lipid bilayers on
mica: a study combining AFM, QCM-D, and ellipsometry. Biophysical Journal 2005;
88: 3422–3433.
56 Dixon MC. Quartz crystal microbalance with dissipation monitoring: enabling real-
time characterization of biological materials and their interactions. Journal of
Biomolecular Techniques 2008; 19: 151–158.
57 Keller CA, Kasemo B. Surface speciﬁc kinetics of lipid vesicle adsorption measured
with a quartz crystal microbalance. Biophysical Journal 1998; 75: 1397–1402.
58 Segers T, De Rond L, De Jong N et al. Stability of monodisperse phospholipid-
coated microbubbles formed by ﬂow-focusing at high production rates. Langmuir
2016; 32: 3937–3944.
59 Spanova M, Zweytick D, Lohner K et al. Inﬂuence of squalene on lipid particle/
droplet and membrane organization in the yeast Saccharomyces cerevisiae.
Biochimica et Biophysica Acta(BBA)-Molecular and Cell Biology of Lipids 2012; 1821:
647–653.
60 Royal Society of Chemistry. ChemSpider 2015; Available at http://www.chemspi
der.com/.
61 Mico V Developing microbubble-nanodroplet composites for enhanced hydro-
phobic drug delivery. PhD Dissertation, University of Leeds, Leeds, UK, 2017.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2018
Supplementary Information for this article can be found on the Microsystems & Nanoengineering website (http://www.nature.com/
micronano).
Oil layer inside microbubbles
AH Churchman et al
8
Microsystems & Nanoengineering doi:10.1038/micronano.2017.87
